ISSUE 18

September 2021

New York

London Tel: +44 (0) 207 291 4670

PiperSandler.com

PIPER SANDLER

Chemicals M&A Review

the Valence Group

Contents

- Chemicals M&A and Valuations
- Private Equity in Chemicals
- Sector Focus Coating Resins












Highlights

- The Valence Group of Piper Sandler advises on more than US \$20 billion of announced transactions in 2021
- Chemical transaction multiples reach a 20-year high and high tier specialty chemicals trading at 25x EBITDA
- Private equity share of chemicals M&A transactions in 2021 now above 35% for the first time and over US \$20 billion

M&A and Valuations

A year ago, it would have been difficult to believe that we would now be in the midst of an M&A boom. In North America and Europe, acquisitions have been running at elevated levels fuelled by higher growth and profits outlook, as economies start to escape from the Covid induced recessions. Across multiple industries, M&A has been at or close to all-time highs, and chemicals has been no exception and has recovered strongly. As can be seen from Figure 1, monthly volumes of chemicals M&A transactions has continued to climb almost steadily from Q3/Q4 2020.

Figure 1: Monthly Chemicals M&A Volumes



The Valence Group of Piper Sandler and Capiq analysis. Deals above \$10m

The rebound actually started in China but quickly moved to Europe and the US where it has really taken hold. Asia has now softened somewhat, as the next wave of the Covid Delta variant hits those economies (many with lower vaccination rates). Europe and North America have continued to show resilience as we have seen from the number of deal announcements of larger transactions such as:


- Platinum Solenis (CD&R and BASF)
- PTTGC (Thailand) Allnex (Advent)
- Everarc Perimeter Solutions (SK)
- Lone Star AOC (CVC)
- Kerry Niacet (SK)

Just the above five examples amounted to \$15bn in the last few months, emphasising the strength of the market. Certainly from our own view at the Piper Sandler Chemicals Group, having advised on four of the above transactions, the market remains undeniably strong and the most active since 2010.

Corporate profits have rebounded strongly from the lows of Q2/Q3 2020, and with most upstream chemical companies able to increase both volume and pricing, coupled with strong specialty chemicals profits, it is unsurprising stock prices have also continued to rise. Naturally this has led to trading multiples rising as markets reacted to the new profit outlook. Current multiples (12 month LTM EBITDA basis) are now at all-time highs and are at above 14x EBITDA on average for chemicals in 2021 (Figure 2). However, as corporate profits for 2021 start to catch up with the rapid stock price appreciation of H1 2021, we would expect the average multiple to moderate and decline to 12-13x EBITDA by the end of the year.


As also shown in Figure 2, with Q2 results being announced recently, the average trading multiple has already dropped by c. 10% to below 14x EBITDA. The chemical sector subsegments show a similar pattern, as seen in Figure 3, with most segments showing an increase in trading multiples this year but with a tailing off most recently as profits caught up with stock price gains. The exception remains for the high tier specialty segment which continues to increase even in the last few months. Healthy profits, growth, consolidation and M&A (both acquisitions and divestments) continue to support these sub-segment sectors and much of the rise of the trading multiples for chemicals overall.

Figure 2: Chemical Company Trading Multiples



The Valence Group of Piper Sandler and Capiq analysis. Based on c. 90 mainly US and European chemical companies

Figure 3: Trading Multiples by Chemical Segment




Trading multiples for commodity and diversified chemicals have only risen by c. 20-30% in the last 10 years whereas for high tier specialities it is over 100%. The speciality chemicals sector has been the driver of valuation growth overall.

There is currently no sign of the valuation levels of high tier specialty chemicals declining. Large investors are increasingly moving away from stocks in companies linked to oil due to ESG reasons. Many specialty chemicals in areas such as electronic chemicals, flavours and fragrance and food/nutrition related sub-segments offer an attractive alternative.


As shown in Figure 4, valuations in sectors such as electronic chemicals, after a decline early in the last decade, have risen strongly and are typical of many of the high tier speciality segments. The Flavours and Fragrance segment is similar. It is difficult to see how the importance of these segments in a more ESG-focused and post-Covid environment will falter. Valuations are therefore unlikely to decline substantially in the near to mid-term, and chemical company valuations overall will consequently albeit with perhaps remain at current levels, an ever increasing split between high speciality chemicals and the less in favour commodity diversified chemicals. more

Figure 4: Select High Tier Specialty Chemicals Trading Multiples



The Valence Group of Piper Sandler and Capiq analysis. Based on mainly US and European chemical companie

Figure 5: Chemical Company Transaction EBTDA Multiples



The Valence Group of Piper Sandler internal analysis. Disclosed Transactions > c.\$200m

As previously mentioned, with the number of high profile larger transactions, the average valuation multiple, as measured by transaction purchase price, has also increased to 13x EBITDA (Figure 5). The M&A market has been underpinned by continued strong demand for acquisitions, high profits and financial sponsors keen to deploy capital while also considering exits. There is little to suggest this will change in 2021 and acquisitions are expected to continue apace post the summer lull. The expectation is that trading and transaction multiples will converge at c. 13x EBITDA for the year and will very probably mark the highest annual level recorded to date.

Private Equity – Ever Upwards


As indicated above, financial sponsors have been one of the driving forces of M&A in chemicals in the last 6 months. Traditionally, private equity has played a relatively important but secondary role in the chemicals arena. The chemical industry does not always lend itself to the private equity model as the complexity of understanding the technical and market dynamics of more than 220 product/market sectors is normally seen as a partial barrier to the uninitiated.

Furthermore, the cyclicality of many upstream sectors has been seen as a high risk for debt heavy financial structures required by private equity. One only needs to think back to LyondellBasell and Borsodchem to understand the risks attached to these sub-sectors (of course, over the cycle the returns on upstream businesses can be impressive and often better than performance chemicals but a stable cash flow is needed to service high leverage). Typically, financial sponsors have been selective in their investment strategy and heavily favoured performance chemicals. As a consequence, private equity typically only accounts for c. 10-15% of transactions in chemicals by volume.

In recent years, we have seen the rise of sector specialists such as SK Capital Partners and Arsenal Capital who have focused investments in chemicals with great success. Companies such as Carlyle, Bain Capital and Advent International have also achieved significant success in the chemicals sector.

Despite this interest, private equity transaction levels had largely remained approximately constant as a percentage of overall M&A. However, in 2021 private equity has become a driving force in chemicals M&A. More than 35% of acquisitions across chemicals have been backed by financial sponsors (this even excludes sponsor owned company acquisitions). As Figure 6 shows, after a broadly stable c. 7-8 year period of from 2011, private equity is now a major player in the chemical industry and competes head-on with industrial companies for some of the most prized assets.

Figure 6: Private Equity Share of Chemicals M&A (by volume)



The Valence Group of Piper Sandler internal analysis. Up to $Aug \, 1^{M} \, 2021$. By number of transactions. Approximate value indicated for three years is in USS. Only includes private equity backed transactions and excludes portfolio company acquisitions

In line with volumes, total deal value was increased sharply. In 2011, deal value was less than \$2 billion, by 2016 this had risen to c. \$10bn. To date, 2021 has notched up more than \$20bn in financial sponsor led acquisitions. In terms of deal value, private equity accounts for more than 40% of chemicals transactions currently. This is a staggering change in just 10 years.


The strength of private equity can be traced back to several important factors:

- Low interest rates coupled with availability of debt and high leverage levels (currently debt above 6x EBITDA is accessible)
- Huge reserves of capital and need to deploy capital (Figure 7 shows global private equity M&A)
- Continued realignment of the chemical industry to sector specialisation with resulting consolidation/ divestment of businesses
- Increased chemical sector focus from recent successful acquisitions and exits
- Rise of financial sponsors focused on chemicals either wholly or partly
- More flexible approach to exit options and the emergence of Asian buyers at exit

All of these aspects have combined recently with the resulting increase in deal volumes. The availability of low cost debt and access to capital are one of the key current supporting pillars and this has made financial sponsors even more competitive.

Critically, we therefore appear to have reached a tipping point where financial sponsors can now outbid strategic buyers. This has enhanced their ability to acquire companies in auction or bilateral processes boosting their overall success. As a recent example from chemicals, Bain Capital/Cinven outbid strategic companies for the acquisition of Lonza Specialty Ingredients. With the increased attention and focus on the chemicals sector, financial sponsors will, at the current interest rates, continue to grow in importance.


Figure 7: Total Private Equity Acquisitions (All Industries)



Sector Focus - Coatings Resins

The coatings intermediates segment of chemicals encompasses all the coatings resins and additives technologies and products used to produce industrial and decorative paints, coatings, inks and composites. The products manufactured by specialists can include highly complex chemistry across acrylics, polyurethanes, epoxies, polyesters chemistries and are moving inexorably away from solvent to more environmentally friendly water-based chemistries. The products are sold widely to end customers in the paints and coatings industry such as PPG, Akzo-Nobel, Sherwin-Williams and Axalta. There are more than 10-20 companies with significant share in their chosen area(s) as shown in Figure 8.

Figure 8: Coatings Resins - Sector Fragmentation



Source: The Valence Group of Piper Sandler

In common with much of the chemical industry, the sector has seen private equity interest and some M&A activity but has now started to consolidate. In many ways, the sector is typical of the industry with several private equity owners and multiple chemical companies, some of who may consider M&A as part of the industry consolidation. In the mid-term we would expect to see considerable M&A activity as part of this overall consolidation and we have already seen two large transactions in the last 12 months. DSM divested its Coating Resins business (to exit the sector entirely) to Covestro and Advent International is divesting Allnex to PTTGC (Thailand). It is expected that these two deals, of combined value of more than \$6bn, will be the start of expansion of some companies while others exit the space. Mergers also seem probable.

The sector has, until recently, not received much attention as it was fragmented, had multiple technologies, phasing out older products and perhaps most importantly, unclear growth and dynamics. Now with a clearer growth platform for newer or environmentally friendlier products, strong growth in Asia and more committed and focused companies, there is renewed interest in the sector. Expansion and consolidation will inevitably result in more M&A and we expect to see more significant acquisitions in the next years.

Chemicals YTD 2021 Transactions





has acquired



Financial Advisor





Financial Advisor














Financial Advisor



PIPER SANDLER

the Valence Group

Specialization Delivers Special Results

Lead advisor on largest ever chemical LBO

\$11.7 billion

THE CARLYLE GROUP



have acquired the Specialty Chemicals business of



now known as

Nouryon

Financial Advisor

Lead advisor on second largest chemical LBO

\$5.3 billion



is acquiring



from





Financial Advisor

Lead advisor on fourth largest chemical LBO

\$4.7 billion



Cinven

have acquired the Specialty Ingredients business of

Lonza

Financial Advisor

PIPER SANDLER

the Valence Group

Piper Sandler acquired the preeminent chemicals M&A firm, The Valence Group, on April 3, 2020. The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors.

The chemicals team includes a unique combination of professionals with backgrounds in investment banking, strategic consulting and senior management within the chemicals and materials industries, all focused exclusively on providing M&A advisory services to the chemicals sector.



























PIPER SANDLER

the Valence Group



































PIPER SANDLER

the Valence Group


































PIPER SANDLER

the Valence Group